Thanks to @sebastian.bsky.social for the great interview for the @newquantumera.com We talked about #GQE and #VQE and #QML #quantummachinelearning #quantum #compchemsky

Excited to share our latest work, published this morning in Nature Biotechnology! 🎉 We developed a hybrid quantum computing-enhanced generative model to design KRAS inhibitors. Check it out here: rdcu.be/d68Fs.

Some fascinating insights along the way:

Part 1: Exciting news! Our research on quantum drug discovery is now in Nature Biotechnology. A Quantum Computer helped design KRAS inhibitors, an elusive cancer target. These inhibitors were successfully synthesized and tested, marking a milestone in healthcare innovation. 🚀
#QuantumComputing #KRAS

Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors - Nature Biotechnology A hybrid model combines quantum and classical approaches to generate compounds targeting the KRAS protein.

Important paper in @naturebiotech.bsky.social
www.nature.com/articles/s41...

Glad to see our research on thr first #quantum + #ai application with experimental confirmation for #drugdiscovery out in Nature Biotechnology!

@ghazivakili.bsky.social @elonverse.bsky.social Igor Stagljar @thematterlab.bsky.social

Images

Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis Endometriosis is a chronic inflammatory gynecological disease affecting over 190 million women globally, and no curative treatment is currently available. This study identifies two novel therapeutic ...

advanced.onlinelibrary.wiley.com/doi/10.1002/...

Endometriosis is not only a huge unmet medical need where advances in AIDD can help hundreds of millions of women over time but it is also a platform for understanding the many biological processes (including cancer and aging) and therapeutic approaches. This problem must be solved in our lifetime

CUHK is one of the top universities in OBGYN as it gave us non-invasive prenatal diagnostics and testing (NIPD/NIPT) and is the home to *hopefully* the future Nobel laureate, Dennis Lo. This school has advanced experimental models and spectacular clinical base.

Another day, another paper -- and this research paper paves the way to a therapeutic program with very real therapeutic opportunity. Welcome our new paper with CUHK titled "Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis"

PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands - Journal of Experimental & Clinical Cancer Research Background Adenoid cystic carcinoma (ACC) is a rare glandular malignancy, commonly originating in salivary glands of the head and neck. Given its protracted growth, ACC is usually diagnosed in advance...

The team used Insilico Medicine PandaOmics platform with extensive experimental validation.
IMHO, PRMT5+MAT2A could work even better. Share the paper with your PRMT5-enabled friends.
link.springer.com/article/10.1...

And now, many of my friends with PRMT5 inhibitors in their pipelines will take notice. Welcome the new paper from University of Chicago Evgeny Izumchenko's group showing that PRMT5is can serve as powerful agents in adenoid cystic carcinoma of salivary glands.

Huge congratulations to Dominika Wilczok on her first single author paper on generative AI for aging research. This paper has over 170 references and is a gargantuan amount of work.
www.aging-us.com/article/2061...

How AI uncovers new ways to tackle difficult diseases Pharmaceutical firms are turning to AI to find new molecules that might be able to tackle disease.

Inside the great AI drug race: www.bbc.com/news/article...

Progress, Pitfalls, and Impact of AI‐Driven Clinical Trials Since the deep learning revolution of the early 2010s, significant efforts and billions of dollars have been invested in applying artificial intelligence (AI) to drug discovery and development (AIDD)....

If you don't have quantitative benchmarks, you can not improve. Check out Domika Wilczok's paper on challenges in AI pharma R&D
ascpt.onlinelibrary.wiley.com/doi/full/10....

Skinly: A novel handheld IoT device for validating biophysical skin characteristics Background Recent advancements in artificial intelligence have revolutionized dermatological diagnostics. These technologies, particularly machine learning (ML), including deep learning (DL), have s.....

Don't forget to read about the best device to measure your skin over time in the context of your daily life.
Thousands of meta clinical trials worldwide now.
onlinelibrary.wiley.com/doi/10.1111/...

Great to be here! 🙏

Hello, @aspuru.bsky.social , hola from BlueSky!

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor - Nature Biotechnology Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.

I noticed that @natureportfolio.bsky.social started tracking BlueSky in @altmetric.com @altmetric.bsky.social , so I decided to join.
Check out our latest paper in @naturebiotech.bsky.social
www.nature.com/articles/s41...

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor - Nature Biotechnology Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.

www.nature.com/articles/s41...

4/ This is a game-changer for 40% of IBD patients who lack effective treatments. Combining AI with biology accelerates therapeutic breakthroughs. 🌟
Full study: [Nature Biotech DOI link]
#IBD #AIinMedicine #DrugDiscovery

3/ Key outcomes: ✅ ISM012-042 is more effective than SOC treatments (e.g., mesalamine) in murine colitis models. ✅ No systemic side effects due to gut-restricted PK. ✅ Phase 1 trials underway (NCT06012578), making strides toward patient-ready IBD therapies. 💊

2/ ISM012-042 leverages AI-driven drug design (Chemistry42 platform) to overcome limitations of systemic PHD inhibitors, ensuring colon-targeted action while minimizing off-target effects. Preclinical results show:

Enhanced mucosal healing 🛡️
Reduced inflammation 🔥
Restored gut barrier 🧬

1/ 🚨 Breakthrough in IBD treatment! Insilico Medicine's AI-developed gut-restricted PHD inhibitor, ISM012-042, offers a novel solution for intestinal inflammation and mucosal barrier repair. 🚀 Read on for key findings from the latest @NatureBiotech study. 🧵

The 12th ARDD will transpire 25-29th of August, 2025 - mark your calendars for the largest aging research biotechnology conference on the planet!